510(k) device
Zeta Navigation System (ZNS131-US)
Zeta Surgical, Inc. · Extracranial Positional System For A Transcranial Magnetic Stimulation System (SGE, Class II) · First FDA decision Oct 10, 2025, newest Oct 10, 2025Depression
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "Zeta"
MAUDE reports
5
Brand "Zeta", since 2015
PubMed studies
52,049
Mentioning "Zeta"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Zeta Navigation System (ZNS131-US)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K251927 · Decided Oct 10, 2025 · 109 days after receipt
Device type: Extracranial Positional System For A Transcranial Magnetic Stimulation System (SGE) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcranial Magnetic StimulationLocal determinationIn effectL33398Wellpoint FederalUpdated Jul 16, 2026
- Transcranial Magnetic StimulationProposed local determinationProposedDL33398National Government Services, Inc.Updated Mar 27, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL34641WPS Insurance CorporationUpdated Mar 20, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL37086Noridian Healthcare Solutions, LLCUpdated Aug 6, 2025
- Repetitive Transcranial Magnetic Stimulation (rTMS) in AdultsLocal determinationIn effectL34869Palmetto GBAUpdated Jan 7, 2025
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL36469CGS Administrators, LLCUpdated May 30, 2024
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "Zeta", any status and sponsor, newest update first.
- A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS TrialPivotal-lookingRecruiting
NeuroRx, Inc.Not on our public-company list
NCT07227103 · 240 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2027
Device: Neuronavigated robotic-enabled TMS; Sham TMS · For: Treatment Resistant Depression; Treatment Resistant Depression (TRD)
Sites: Sarasota, Florida; West Palm Beach, Florida; Belmont, Massachusetts
National Cancer Institute (NCI)NIH
NCT07162038 · 155 participants (planned) · Start Nov 14, 2025 · Primary completion Nov 1, 2030
Device: CD19 Flow Cytometry Assay; CD19 Immunohistochemical Assay · For: Hematologic Malignancies; Hematologic Neoplasms
Sites: Bethesda, Maryland
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Zeta", and for the whole product code for context.
This brand
5 reports: 5 malfunction, 0 injury, 0 death
Whole product code SGE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
- MINI VISION; MULTI LINK ZETAMalfunction
MW5137315 · Received Aug 12, 2023
Device type: Stent, Coronary (MAF)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- MULTI-LINK RX ZETA CORONARY STENT SYSTEMMalfunction
2024168-2017-00542 · Received Jan 17, 2017 · Event dated Dec 25, 2016
Device type: Stent, Coronary (MAF)
Device problem as coded: Detachment Of Device Component; Improper or Incorrect Procedure or Method; Failure to Advance
Patient problem as coded: No Consequences Or Impact To Patient
- MULTI-LINK RX ZETA CORONARY STENT SYSTEMMalfunction
2024168-2016-05627 · Received Aug 23, 2016 · Event dated Aug 12, 2016
Device type: Stent, Coronary (MAF)
Device problem as coded: Detachment Of Device Component; Failure to Advance
Patient problem as coded: No Consequences Or Impact To Patient
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Zeta"[tiab]. The summary above synthesizes these.
- Eukaryotic DNA polymerase ζ.
Makarova AV, Burgers PM · DNA Repair (Amst) · 2015Research Support, N.I.H., Extramural, Review
- TGF-β-induced IκB-ζ controls Foxp3 gene expression.
MaruYama T · Biochem Biophys Res Commun · 2015Research Support, Non-U.S. Gov't
- Disruption of DNA polymerase ζ engages an innate immune response.
Martin SK, Tomida J, Wood RD · Cell Rep · 2021Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Zeta potential of crude oil in aqueous solution.
Collini H, Jackson MD · Adv Colloid Interface Sci · 2023Review
- PKC-ζ Aggravates Doxorubicin-Induced Cardiotoxicity by Inhibiting Wnt/β-Catenin Signaling.
Cao YJ, Li JY, Wang PX, et al. · Front Pharmacol · 2022
- Antitoxin ε Reverses Toxin ζ-Facilitated Ampicillin Dormants.
Moreno-Del Álamo M, Marchisone C, Alonso JC · Toxins (Basel) · 2020Research Support, Non-U.S. Gov't
- Solvent Influence on Zeta Potential of Stationary Phase-Mobile Phase Interface.
Dembek M, Bocian S, Buszewski B · Molecules · 2022
- DNA polymerase ζ in DNA replication and repair.
Martin SK, Wood RD · Nucleic Acids Res · 2019Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- A sophisticated mechanism governs Pol ζ activity in response to replication stress.
Li C, Fan S, Li P, et al. · Nat Commun · 2024
- Zeta potentials of PDMS surfaces modified with poly(ethylene glycol) by physisorption.
Song Y, Feng A, Liu Z, et al. · Electrophoresis · 2020Research Support, Non-U.S. Gov't
- Clustering of the ζ-Chain Can Initiate T Cell Receptor Signaling.
Ma Y, Lim YJ, Benda A, et al. · Int J Mol Sci · 2020
- Amplitudes and the Riemann Zeta Function.
Remmen GN · Phys Rev Lett · 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.